AI speeds up drug design for Parkinson’s by ten-fold

Researchers have used artificial intelligence techniques to massively accelerate the search for Parkinson’s disease treatments. The researchers designed and used an AI-based strategy to identify compounds that block the clumping, or aggregation, of alpha-synuclein, the protein that characterises Parkinson’s.

​Researchers have used artificial intelligence techniques to massively accelerate the search for Parkinson’s disease treatments. The researchers designed and used an AI-based strategy to identify compounds that block the clumping, or aggregation, of alpha-synuclein, the protein that characterises Parkinson’s. Researchers have used artificial intelligence techniques to massively accelerate the search for Parkinson’s disease treatments. The researchers designed and used an AI-based strategy to identify compounds that block the clumping, or aggregation, of alpha-synuclein, the protein that characterises Parkinson’s. 

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top